Xenon Pharmaceuticals Inc
XENE39.094USD
+0.684+1.78%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
3.01BCap. mercado
PérdidaP/E TTM
Más Datos de Xenon Pharmaceuticals Inc Compañía
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.
Información de Xenon Pharmaceuticals Inc
Símbolo de cotizaciónXENE
Nombre de la empresaXenon Pharmaceuticals Inc
Fecha de salida a bolsaOct 17, 2014
Director ejecutivoMr. Ian C. Mortimer, CPA
Número de empleados316
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 17
Dirección3650 Gilmore Way
CiudadVANCOUVER
Bolsa de valoresNASDAQ Global Market Consolidated
PaísCanada
Código postalV5G 4W8
Teléfono16044843300
Sitio Webhttps://www.xenon-pharma.com/
Símbolo de cotizaciónXENE
Fecha de salida a bolsaOct 17, 2014
Director ejecutivoMr. Ian C. Mortimer, CPA
Ejecutivos de Xenon Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Principal Operating Officer, Director
President, Chief Executive Officer, Principal Operating Officer, Director
45.60K
--
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Mr. Thomas J. (Tucker) Kelly, J.D.
Mr. Thomas J. (Tucker) Kelly, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
--
--
Dr. Gillian M. Cannon, Ph.D.
Dr. Gillian M. Cannon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Justin Gover
Mr. Justin Gover
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Principal Operating Officer, Director
President, Chief Executive Officer, Principal Operating Officer, Director
45.60K
--
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Mr. Thomas J. (Tucker) Kelly, J.D.
Mr. Thomas J. (Tucker) Kelly, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
Canada
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 31 de oct
Actualizado: vie., 31 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
8.29%
Avoro Capital Advisors LLC
6.99%
Driehaus Capital Management, LLC
5.61%
BlackRock Institutional Trust Company, N.A.
5.33%
Braidwell LP
4.67%
Otro
69.12%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
8.29%
Avoro Capital Advisors LLC
6.99%
Driehaus Capital Management, LLC
5.61%
BlackRock Institutional Trust Company, N.A.
5.33%
Braidwell LP
4.67%
Otro
69.12%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
48.35%
Investment Advisor
33.63%
Hedge Fund
23.40%
Private Equity
1.90%
Research Firm
1.51%
Sovereign Wealth Fund
0.82%
Pension Fund
0.71%
Bank and Trust
0.34%
Individual Investor
0.14%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
446
85.67M
110.86%
-494.45K
2025Q2
418
85.39M
111.27%
+856.94K
2025Q1
434
79.94M
104.19%
-5.23M
2024Q4
434
79.81M
104.31%
-4.80M
2024Q3
425
77.49M
102.39%
-3.82M
2024Q2
431
76.92M
102.03%
-4.12M
2024Q1
421
76.68M
101.81%
-2.76M
2023Q4
404
75.13M
102.42%
+7.65M
2023Q3
386
64.60M
99.41%
-3.93M
2023Q2
377
64.25M
101.09%
-4.03M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
6.40M
8.3%
+244.00K
+3.96%
Jun 30, 2025
Avoro Capital Advisors LLC
5.40M
7%
-341.67K
-5.95%
Jun 30, 2025
Driehaus Capital Management, LLC
4.34M
5.62%
-249.21K
-5.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.12M
5.34%
+3.47M
+534.85%
Jun 30, 2025
Braidwell LP
3.61M
4.68%
+895.15K
+33.03%
Jun 30, 2025
Janus Henderson Investors
3.58M
4.64%
+252.64K
+7.60%
Jun 30, 2025
Capital International Investors
3.18M
4.13%
+92.82K
+3.01%
Jun 30, 2025
Commodore Capital LP
3.02M
3.92%
+700.00K
+30.11%
Jun 30, 2025
Polar Capital LLP
2.70M
3.51%
+80.22K
+3.06%
Jun 30, 2025
Fidelity Institutional Asset Management
2.48M
3.22%
+352.87K
+16.57%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
4.25%
ALPS Medical Breakthroughs ETF
1.85%
Goldman Sachs Future Health Care Equity ETF
1.03%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
First Trust Multi-Manager Small Cap Opportunities ETF
0.58%
JPMorgan Fundamental Data Science Small Core ETF
0.52%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.45%
JPMorgan Healthcare Leaders ETF
0.41%
ProShares Ultra Nasdaq Biotechnology
0.32%
Invesco Nasdaq Biotechnology ETF
0.31%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción4.25%
ALPS Medical Breakthroughs ETF
Proporción1.85%
Goldman Sachs Future Health Care Equity ETF
Proporción1.03%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.88%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporción0.58%
JPMorgan Fundamental Data Science Small Core ETF
Proporción0.52%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporción0.45%
JPMorgan Healthcare Leaders ETF
Proporción0.41%
ProShares Ultra Nasdaq Biotechnology
Proporción0.32%
Invesco Nasdaq Biotechnology ETF
Proporción0.31%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
